Feasibility study to determine whether new generation catalytic antibodies can overcome existing limitations for future use in clinical settings.

可行性研究，以确定新一代催化抗体是否可以克服现有的限制，以便将来在临床环境中使用。

• 批准号: BB/N012356/1
• 负责人: Nigel Scrutton
• 金额: $ 15.22万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FN012356%2F1
• 关键词: Feasibility; study; determine; whether; new

Research into the therapeutic use of catalytic antibodies stretches back over 30 years but to date there is not a single example of success in the clinic. This is in stark contrast to the ever-expanding use of antibodies to treat a range of diseases when they are used as binders and modulators of protein function. This feasibility study aims to answer whether this imbalance can be redressed through the utilisation of novel techniques now available in antibody research (specifically improved antibody phage libraries and bispecific antibody technologies) combined with an examination of the therapeutic and commercial potential of catalytic antibodies should the primary issues of poor catalytic efficiency and selectivity as compared to the natural enzymes be addressed. As a test case we have chosen to try and make catalytic antibodies that share the therapeutically useful properties of streptococcal IgG endopeptidase but lack the enzyme's immunogenicity, which seriously limits its clinical potential.

对催化抗体的治疗用途的研究可以追溯到30多年前，但迄今为止，在临床上还没有一个成功的例子。这与抗体作为蛋白质功能的结合剂和调节剂用于治疗一系列疾病的不断扩大的用途形成鲜明对比。该可行性研究旨在回答这种不平衡是否可以通过利用抗体研究中现有的新技术（特别是改进的抗体噬菌体文库和双特异性抗体技术）结合催化抗体的治疗和商业潜力的检查来纠正，与天然酶相比，催化效率和选择性差的主要问题应该得到解决。作为一个测试案例，我们选择尝试和制造催化抗体，这些抗体具有链球菌IgG内肽酶的治疗有用特性，但缺乏该酶的免疫原性，这严重限制了其临床潜力。